MX2021002633A - Dispersiones solidas de bendamustina e infusion continua. - Google Patents
Dispersiones solidas de bendamustina e infusion continua.Info
- Publication number
- MX2021002633A MX2021002633A MX2021002633A MX2021002633A MX2021002633A MX 2021002633 A MX2021002633 A MX 2021002633A MX 2021002633 A MX2021002633 A MX 2021002633A MX 2021002633 A MX2021002633 A MX 2021002633A MX 2021002633 A MX2021002633 A MX 2021002633A
- Authority
- MX
- Mexico
- Prior art keywords
- solid dispersions
- continuous infusion
- bendamustine
- bendamustine hydrochloride
- degradants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que comprenden mostaza de nitrógeno, por ejemplo, clorhidrato de bendamustina, dispersiones sólidas sustancialmente libres de degradantes. También se proporcionan métodos para producir y administrar mostazas de nitrógeno y en particular dispersiones sólidas e clorhidrato de bendamustina sustancialmente libres de degradantes. Las composiciones farmacéuticas pueden ser usadas para cualquier enfermedad que es sensible al tratamiento con clorhidrato de bendamustina, tal como enfermedades neoplásicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461952624P | 2014-03-13 | 2014-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002633A true MX2021002633A (es) | 2021-05-12 |
Family
ID=52684713
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011236A MX2016011236A (es) | 2014-03-13 | 2015-03-04 | Dispersiones solidas de bendamustina e infusion continua. |
MX2022006770A MX2022006770A (es) | 2014-03-13 | 2016-08-30 | Dispersiones solidas de bendamustina e infusion continua. |
MX2021002633A MX2021002633A (es) | 2014-03-13 | 2016-08-30 | Dispersiones solidas de bendamustina e infusion continua. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011236A MX2016011236A (es) | 2014-03-13 | 2015-03-04 | Dispersiones solidas de bendamustina e infusion continua. |
MX2022006770A MX2022006770A (es) | 2014-03-13 | 2016-08-30 | Dispersiones solidas de bendamustina e infusion continua. |
Country Status (9)
Country | Link |
---|---|
US (5) | US9320730B2 (es) |
EP (1) | EP3116481A1 (es) |
JP (3) | JP6883428B2 (es) |
CN (2) | CN106102722A (es) |
AU (3) | AU2015229842B2 (es) |
CA (1) | CA2941632C (es) |
IL (1) | IL247739A0 (es) |
MX (3) | MX2016011236A (es) |
WO (1) | WO2015138199A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3043648B1 (en) | 2013-08-27 | 2023-09-20 | Vasilios VOUDOURIS | Bendamustine pharmaceutical compositions |
EP3484466A1 (en) * | 2016-07-13 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
JP7464995B2 (ja) * | 2018-03-29 | 2024-04-10 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液体薬学的製剤 |
CN108324691B (zh) * | 2018-04-11 | 2019-03-08 | 健进制药有限公司 | 一种注射用卡莫司汀冻干制剂及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19757224A1 (de) * | 1997-12-22 | 1999-07-01 | Bayer Ag | Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation |
JP2000281561A (ja) * | 1999-03-26 | 2000-10-10 | Ajinomoto Co Inc | 新規溶媒法固体分散体製剤 |
US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
CN101933923A (zh) * | 2004-11-05 | 2011-01-05 | 赛福伦公司 | 癌症治疗 |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
WO2006105399A1 (en) * | 2005-03-31 | 2006-10-05 | Bristol-Myers Squibb Company | Methods for administering ixabepilone |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
CN102149715A (zh) * | 2008-09-17 | 2011-08-10 | Cj第一制糖株式会社 | 肝适能的稳定化固态分散物及其制备方法 |
MX2011002936A (es) * | 2008-09-25 | 2011-04-11 | Cephalon Inc | Formulaciones liquidas de bendamustina. |
CN102413816A (zh) | 2009-04-28 | 2012-04-11 | 赛福伦公司 | 苯达莫司汀的口服制剂 |
PL3158991T3 (pl) * | 2010-01-28 | 2021-09-27 | Eagle Pharmaceuticals, Inc. | Preparaty bendamustyny |
WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
US20140142153A1 (en) | 2011-01-25 | 2014-05-22 | Dr. Reddy's Laboratories, Inc. | Bendamustine formulations |
WO2013102920A1 (en) * | 2011-11-18 | 2013-07-11 | Astron Research Limited | Stable lyophilized formulation of bendamustine |
WO2013103801A1 (en) * | 2012-01-04 | 2013-07-11 | Hospira, Inc. | Pharmaceutical spray drying |
US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
IN2012DE00337A (es) * | 2012-02-06 | 2015-04-10 | Fresenius Kabi Oncology Ltd | |
EP2641592A1 (en) * | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
EP3043648B1 (en) * | 2013-08-27 | 2023-09-20 | Vasilios VOUDOURIS | Bendamustine pharmaceutical compositions |
-
2015
- 2015-03-04 JP JP2016555955A patent/JP6883428B2/ja active Active
- 2015-03-04 AU AU2015229842A patent/AU2015229842B2/en active Active
- 2015-03-04 CN CN201580012656.8A patent/CN106102722A/zh active Pending
- 2015-03-04 MX MX2016011236A patent/MX2016011236A/es unknown
- 2015-03-04 EP EP15710366.4A patent/EP3116481A1/en active Pending
- 2015-03-04 WO PCT/US2015/018725 patent/WO2015138199A1/en active Application Filing
- 2015-03-04 CA CA2941632A patent/CA2941632C/en active Active
- 2015-03-04 CN CN202210568961.7A patent/CN115350155A/zh active Pending
- 2015-03-04 US US14/638,543 patent/US9320730B2/en active Active
-
2016
- 2016-04-20 US US15/134,122 patent/US9907752B2/en active Active
- 2016-08-30 MX MX2022006770A patent/MX2022006770A/es unknown
- 2016-08-30 MX MX2021002633A patent/MX2021002633A/es unknown
- 2016-09-11 IL IL247739A patent/IL247739A0/en unknown
-
2018
- 2018-02-26 US US15/905,640 patent/US20180185279A1/en not_active Abandoned
-
2019
- 2019-11-29 JP JP2019217619A patent/JP2020055831A/ja active Pending
-
2020
- 2020-09-17 AU AU2020233707A patent/AU2020233707A1/en not_active Abandoned
-
2021
- 2021-07-20 US US17/381,054 patent/US20210346289A1/en not_active Abandoned
-
2022
- 2022-04-18 JP JP2022068104A patent/JP2022095923A/ja active Pending
- 2022-08-05 AU AU2022211893A patent/AU2022211893A1/en active Pending
-
2023
- 2023-07-20 US US18/224,232 patent/US20230364017A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230364017A1 (en) | 2023-11-16 |
CA2941632A1 (en) | 2015-09-17 |
US20180185279A1 (en) | 2018-07-05 |
MX2022006770A (es) | 2022-06-22 |
US9907752B2 (en) | 2018-03-06 |
AU2015229842B2 (en) | 2020-06-25 |
US9320730B2 (en) | 2016-04-26 |
JP2022095923A (ja) | 2022-06-28 |
AU2022211893A1 (en) | 2022-09-15 |
CA2941632C (en) | 2023-10-24 |
JP6883428B2 (ja) | 2021-06-09 |
US20160310422A1 (en) | 2016-10-27 |
US20150258069A1 (en) | 2015-09-17 |
MX2016011236A (es) | 2017-04-06 |
WO2015138199A1 (en) | 2015-09-17 |
CN106102722A (zh) | 2016-11-09 |
EP3116481A1 (en) | 2017-01-18 |
CN115350155A (zh) | 2022-11-18 |
JP2020055831A (ja) | 2020-04-09 |
IL247739A0 (en) | 2016-11-30 |
AU2020233707A1 (en) | 2020-10-15 |
AU2015229842A1 (en) | 2016-09-15 |
JP2017507958A (ja) | 2017-03-23 |
US20210346289A1 (en) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ734233A (en) | Pharmaceutical compositions comprising meloxicam | |
ECSP16075472A (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
IN2013MU03583A (es) | ||
IN2013MU00711A (es) | ||
MX2021002633A (es) | Dispersiones solidas de bendamustina e infusion continua. | |
EA201591758A8 (ru) | Подкожное введение adamts13 | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
MX2016015261A (es) | Dispersion solida de allisartan isoproxilo y su composicion. | |
MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
MX2016011706A (es) | Formulaciones de progesterona. | |
MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
NZ725354A (en) | Transdermal formulations of pergolide and uses thereof | |
WO2014170769A3 (en) | Bendamustine lyophilized pharmaceutical compositions | |
UA115417U (xx) | Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі | |
IN2013MU01510A (es) | ||
IN2013MU03855A (es) | ||
IN2014MU00667A (es) |